A Dose Finding Study of CC-96673 in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma

Exclusion Criteria

• •1. Participant has cancer with symptomatic central nervous system (CNS) involvement
• •2. Participant is on chronic systemic immunosuppressive therapy or corticosteroids or subjects with clinically significant graft-versus-host disease (GVHD). Intranasal, inhaled, topical, or local corticosteroid injections, or steroids as premedication for hypersensitivity reactions are exceptions to this criterion.
• •3. Inadequate cardiac function or significant cardiovascular disease
• •4. Participant has received prior investigational therapy directed at CD47 or SIRPα.
• •5. Participant had major surgery ≤ 2 weeks prior to starting CC-96673.
• •6. Participant is a pregnant or lactating female or intends to become pregnant during participation of the study.
• •7. Participant has known active human immunodeficiency virus (HIV) infection.
• •8. Participant has active hepatitis B or C (HBV/HCV) infection.
• •9. Ongoing treatment with chronic, therapeutic dosing of anti-coagulants.
• •10. History of autoimmune hemolytic anemia or autoimmune thrombocytopenia.
• •11. History of concurrent second cancers requiring active, ongoing systemic treatment.
• •12. Participant has any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study.